연구동향 분석
박사

Antitumor effect of Astragalin from Paeonia lactiflora in melanoma skin cancer cells

유옥희 2015년

논문상세정보
인용/피인용
' Antitumor effect of Astragalin from Paeonia lactiflora in melanoma skin cancer cells' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • apoptosis
  • astragalin
  • mcl-1
  • melanoma
  • papr
  • tunel
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
628 0

0.0%

' Antitumor effect of Astragalin from Paeonia lactiflora in melanoma skin cancer cells' 의 참고문헌

  • Zilla MK, Nayak D, Amin H, Nalli Y, Rah B, Chakraborty S, Kitchlu S,Goswami A & Ali A (2014) 4'-Demethyl-deoxypodophyllotoxin glucoside isolatedfrom Podophyllum hexandrum exhibits potential anticancer activities by alteringChk-2 signaling pathway in MCF-7 breast cancer cells. Chem Biol Interact 224C,100-107.
  • Wang M, Yu T, Zhu C, Sun H, Qiu Y, Zhu X & Li J (2014) Resveratroltriggers protective autophagy through the ceramide/Akt/mTOR pathway in? ? melanoma B16 cells. Nutr Cancer 66, 435-440.
  • Thunell LK, Bivik C, Waster P, Fredrikson M, Stjernstrom A, Synnerstad I,Rosdahl I & Enerback C (2014) MDM2 SNP309 promoter polymorphism confersrisk for hereditary melanoma. Melanoma Res 24, 190-197.
  • Sheard MA (1997) Apoptosis update: to be, or not to be, and how toarrange the latter. Meeting review. Neoplasma 44, 202-204.? ?
  • Sasaki M, Kondo M, Sato K, Umeda M, Kawabata K, Takahashi Y, SuzukiT, Matsunaga K & Inoue S (2014) Rhododendrol, a depigmentation-inducingphenolic compound, exerts melanocyte cytotoxicity via a tyrosinase-dependentmechanism. Pigment Cell Melanoma Res 27, 754-763.
  • Saika K & Sobue T (2013) [Cancer statistics in the world]. Gan ToKagaku Ryoho 40, 2475-2480.
  • Routier E, Robert C & Mateus C (2014) [Immunotherapies and melanoma].Bull Cancer 101 Suppl 2, S13-24.
  • Millington GW (2013) Mutations of the BRAF gene in human cancer, byDavies et al. (Nature 2002; 417: 949-54). Clin Exp Dermatol 38, 222-223.? ?
  • Livingstone E, Zimmer L, Vaubel J & Schadendorf D (2014) BRAF, MEKand KIT inhibitors for melanoma: adverse events and their management. Chin Clin? ? Oncol 3, 29.
  • Li F, Liang D, Yang Z, Wang T, Wang W, Song X, Guo M, Zhou E, Li D,Cao Y & Zhang N (2013) Astragalin suppresses inflammatory responses via down? ? regulation of NF-kappaB signaling pathway in lipopolysaccharide-induced mastitisin a murine model. Int Immunopharmacol 17, 478-482.
  • Lee YH, Wang E, Kumar N & Glickman RD (2014) Ursolic aciddifferentially modulates apoptosis in skin melanoma and retinal pigment epithelialcells exposed to UV-VIS broadband radiation. Apoptosis 19, 816-828.
  • Lee KT, Choi JH, Kim DH, Son KH, Kim WB, Kwon SH & Park HJ(2001) Constituents and the antitumor principle of Allium victorialis var.platyphyllum. Arch Pharm Res 24, 44-50.
  • Lee KH, Tagahara K, Suzuki H, Wu RY, Haruna M, Hall IH, Huang HC,Ito K, Iida T & Lai JS (1981) Antitumor agents. 49 tricin, kaempferol-3-O-beta-Dglucopyranosideand (+)-nortrachelogenin, antileukemic principles fromWikstroemia indica. J Nat Prod 44, 530-535.
  • Kim MS & Kim SH (2011) Inhibitory effect of astragalin on expression oflipopolysaccharide-induced inflammatory mediators through NF-kappaB inmacrophages. Arch Pharm Res 34, 2101-2107.
  • Kim DS, Kang YM, Jin WY, Sung YY, Choi G & Kim HK (2014)Antioxidant activities and polyphenol content of leaf extracts collected fromvarying regions. Biomed Rep 2, 675-680.
  • Ke M, Hu XQ, Ouyang J, Dai B & Xu Y (2012) The effect of astragalin onthe VEGF production of cultured Muller cells under high glucose conditions.Biomed Mater Eng 22, 113-119.
  • Kaushik G, Venugopal A, Ramamoorthy P, Standing D, Subramaniam D,Umar S, Jensen RA, Anant S & Mammen JM (2014) Honokiol inhibits melanomastem cells by targeting notch signaling. Mol Carcinog.
  • Karass M, Naguib MM, Elawabdeh N, Cundiff CA, Thomason J, SteelmanCK, Cone R, Schwenkter A, Jordan C & Shehata BM (2015) Xerodermapigmentosa: three new cases with an in depth review of the genetic and clinicalcharacteristics of the disease. Fetal Pediatr Pathol 34, 120-127.? ?
  • Kanduc D, Mittelman A, Serpico R, Sinigaglia E, Sinha AA, Natale C,Santacroce R, Di Corcia MG, Lucchese A, Dini L, Pani P, Santacroce S, Simone S,Bucci R & Farber E (2002) Cell death: apoptosis versus necrosis (review).International journal of oncology 21, 165-170.
  • Johnson MI & Hamdy FC (1998) Apoptosis regulating genes in prostatecancer (review). Oncology reports 5, 553-557.
  • Han JT, Bang MH, Chun OK, Kim DO, Lee CY & Baek NI (2004)? ? Flavonol glycosides from the aerial parts of Aceriphyllum rossii and theirantioxidant activities. Arch Pharm Res 27, 390-395.
  • Ghosh S, Bishayee K & Khuda-Bukhsh AR (2014) Graveoline isolatedfrom ethanolic extract of Ruta graveolens triggers apoptosis and autophagy in skinmelanoma cells: a novel apoptosis-independent autophagic signaling pathway.Phytother Res 28, 1153-1162.
  • Gheorgheosu D, Duicu O, Dehelean C, Soica C & Muntean D (2014)Betulinic acid as a potent and complex antitumor phytochemical: a minireview.Anticancer Agents Med Chem 14, 936-945.
  • Elmore S. 2007. Apoptosis: a review of programmed cell death. Toxicologic pathology 35: 495-516.
  • Egger K & Keil M (1969) [Flavoneglycosides in the flowers of Paeoniaarborea and P. suffruticosa]. Planta 88, 154-156.
  • Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z & Aaronson SA(2003) BRAF oncogenic mutations correlate with progression rather than initiationof human melanoma. Cancer Res 63, 3883-3885.
  • Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J,Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y,Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A,Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C,Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G,Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW,Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R,Marshall CJ, Wooster R, Stratton MR & Futreal PA (2002) Mutations of the BRAFgene in human cancer. Nature 417, 949-954.
  • Corrie P, Hategan M, Fife K & Parkinson C (2014) Management ofmelanoma. Br Med Bull 111, 149-162.
  • Clairwood M, Ricketts J, Grant-Kels J & Gonsalves L (2014) Melanoma inskin of color in Connecticut: an analysis of melanoma incidence and stage atdiagnosis in non-Hispanic blacks, non-Hispanic whites, and Hispanics. Int JDermatol 53, 425-433.
  • Burmistrova O, Quintana J, Diaz JG & Estevez F (2011) Astragalinheptaacetate-induced cell death in human leukemia cells is dependent on caspasesand activates the MAPK pathway. Cancer Lett 309, 71-77.
  • Bristow BN, Casil J, Sorvillo F, Basurto-Davila R & Kuo T (2013)Melanoma-related mortality and productivity losses in the USA, 1990-2008.Melanoma Res 23, 331-335.
  • Berrocal A, Cabanas L, Espinosa E, Fernandez-de-Misa R, Martin-AlgarraS, Martinez-Cedres JC, Rios-Buceta L & Rodriguez-Peralto JL (2014) Melanoma:diagnosis, staging, and treatment. Consensus group recommendations. Adv Ther 31,945-960.
  • Awad MM & Sullivan RJ (2015) Dabrafenib in combination withtrametinib for the treatment of metastatic melanoma. Expert Rev Clin Pharmacol 8,25-33.
  • Aoude LG, Wadt KA, Pritchard AL & Hayward NK (2015) Genetics offamilial melanoma: 20 years after CDKN2A. Pigment Cell Melanoma Res 28, 148-160.